LVMH Moet Hennessy Louis Vuitton (0HAU) Gets a Hold from Jefferies
In a report released yesterday, James Grzinic from Jefferies maintained a Hold rating on LVMH Moet Hennessy Louis Vuitton (0HAU – Research Report), with a price target of €460.00.
Confident Investing Starts Here:
Grzinic covers the Consumer Cyclical sector, focusing on stocks such as Compagnie Financiere Richemont SA, Ferrari, and adidas AG. According to TipRanks, Grzinic has an average return of 4.7% and a 59.63% success rate on recommended stocks.
In addition to Jefferies, LVMH Moet Hennessy Louis Vuitton also received a Hold from HSBC's Erwan Rambourg in a report issued on May 27. However, on the same day, Bernstein maintained a Buy rating on LVMH Moet Hennessy Louis Vuitton (LSE: 0HAU).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
5 minutes ago
- Business Insider
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR) Receives a Buy from Bell Potter
In a report released today, Martyn Jacobs from Bell Potter maintained a Buy rating on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR – Research Report), with a price target of A$2.25. The company's shares closed last Friday at A$1.17. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Jacobs covers the Healthcare sector, focusing on stocks such as EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh, Trajan Group Holdings Ltd, and Medical Developments International Limited. According to TipRanks, Jacobs has an average return of -21.1% and a 13.58% success rate on recommended stocks. Currently, the analyst consensus on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh is a Strong Buy with an average price target of A$2.80, implying a 140.34% upside from current levels. In a report released on May 29, Wilsons also maintained a Buy rating on the stock with a A$3.00 price target.
Business Insider
5 minutes ago
- Business Insider
Citi Remains a Sell on Commonwealth Bank of Australia (CBA)
Citi analyst Thomas Strong maintained a Sell rating on Commonwealth Bank of Australia (CBA – Research Report) today and set a price target of A$100.00. The company's shares closed last Friday at A$179.90. Confident Investing Starts Here: Strong covers the Financial sector, focusing on stocks such as Commonwealth Bank of Australia, ANZ Group Holdings, and Macquarie Group Limited. According to TipRanks, Strong has an average return of -6.9% and a 32.00% success rate on recommended stocks. Commonwealth Bank of Australia has an analyst consensus of Strong Sell, with a price target consensus of A$116.34, a -35.33% downside from current levels. In a report released on May 30, J.P. Morgan also maintained a Sell rating on the stock with a A$120.00 price target. CBA market cap is currently A$300.8B and has a P/E ratio of 30.80. Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CBA in relation to earlier this year.
Business Insider
6 minutes ago
- Business Insider
Citi Sticks to Its Buy Rating for LENZ Therapeutics (LENZ)
In a report released today, Yigal Nochomovitz from Citi maintained a Buy rating on LENZ Therapeutics (LENZ – Research Report), with a price target of $45.00. The company's shares closed today at $31.22. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Nochomovitz is a 4-star analyst with an average return of 3.5% and a 38.98% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, Summit Therapeutics, and Arvinas Holding Company. LENZ Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $47.43.
